SEARCH

SEARCH BY CITATION

References

  • Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ. 1997. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene 14:603609.
  • Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown MA, Tavtigian SV, Goldgar DE, Young JP, Spurdle AB. 2009. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat 30:757770.
  • Balasubramanian S, Xia Y, Freinkman E, Gerstein M. 2005. Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms. Nucleic Acids Res 33:17101721.
  • Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF, Mann GJ. 2005. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun 332:873879.
  • Becker TM, Rizos H, Kefford RF, Mann GJ. 2001. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin Cancer Res 7:32823288.
  • Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD. 1998. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1:421431.
  • Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415417.
  • Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nystrom M, Grimm AJ, Christodoulou J, Oetting WS, Greenblatt MS. 2007. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 28:683693.
  • Chao EC, Velasquez JL, Witherspoon MS, Rozek LS, Peel D, Ng P, Gruber SB, Watson P, Rennert G, Anton-Culver H, Lynch H, Lipkin SM. 2008. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat 29:852860.
  • Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N. 2008. Assessment of functional effects of unclassified genetic variants. Hum Mutat 29:13141326.
  • Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G, Pierotti MA. 2001. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85:836844.
  • Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Załuga E, Maleszka R, Kładny J, Górski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J. 2005. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res, 65:835839.
  • Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. 2007. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873883.
  • Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. 2008. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29:12651272.
  • Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. 2004. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535544.
  • Goldstein AM. 2004. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23:630.
  • Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Melanoma Genetics Consortium (GenoMEL). 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:98189828.
  • Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP. 2003. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 22:11501163.
  • Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN. 1997. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:20612067.
  • Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FB. 2008. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat 29:12921303.
  • Huang X, Shi Z, Wang W, Bai J, Chen Z, Xu J, Zhang D, Fu S. 2007. Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a. Biochem Biophys Res Commun 361:287293.
  • Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark Jr WH, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8:1521.
  • Kannengiesser C, Brookes S, del Arroyo AG, Pham D, Bombled J, Barrois M, Mauffret O, Avril MF, Chompret A, Lenoir GM, Sarasin A, French Hereditary Melanoma Study Group, Peters G, Bressac-de Paillerets B. 2009. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat 30:564574.
  • Koh J, Enders GH, Dynlacht BD, Harlow E. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506510.
  • Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. 2009. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61:677.e114.
  • Murphy JA, Barrantes-Reynolds R, Kocherlakota R, Bond JP, Greenblatt MS. 2004. The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association. Hum Mutat 24:296304.
  • Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. 1995. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 11:18431851.
  • O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD. 2009. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology 18:10881096.
  • Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:12821291.
  • Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. 1995. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114116.
  • Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF. 2001. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:4142441434.
  • Ruas M, Brookes S, McDonald NQ, Peters G. 1999. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene 18:54235434.
  • Sharpless NE. 2005. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576:2238.
  • Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209216.
  • Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G, Tavtigian SV, Goldgar DE, kConFab Investigators. 2008. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis—a report from the kConFab Investigators. J Clin Oncol 26:16571663.
  • Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB. 2008. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29:13271336.
  • Wu D, Rosner GL, Broemeling L. 2005. MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening. Biometrics 61:10561063.
  • Yarbrough WG, Buckmire RA, Bessho M, Liu ET. 1999. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst 91:15691574.